In a regulatory filing, Beam Therapeutics CEO John Evans disclosed the sale of 60,000 common shares of the company on September 30 at a price of $24.6004 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
- Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
- Beam Therapeutics initiated with a Hold at JonesResearch
- Intellia Therapeutics price target lowered to $64 from $80 at Stifel
- Krystal Biotech price target raised to $220 from $204 at Stifel